1. Tanweer A. Khan, Ph.D.
Bridgewater, NJ  908-848-3901
takhan74@gmail.com
https://www.linkedin.com/in/tanweer-khan-014a5b12?trk=nav_responsive_tab_profile
Medicinal Chemist
Recognized Expert in Medicinal Chemistry, Experienced in All Key Aspects of Synthetic and
Process Chemistry
Comprehensive and consistently productive background in research, development, and synthesis of
medicinal chemistry for numerous prestigious organizations in the public and private sectors. Research-
minded, analytic, and results-driven leadership focus with a collaborative personality. Strong ability to
facilitate and negotiate funding for projects, no matter the depth, with proven record of accomplishment
of results.
CORE COMPETENCIES
Medicinal Chemistry  Drug Discovery  HIT Triage  Target Identification  Team Management 
Problem-Solver  Compound Identification  Resource Management  Leadership 
Chemistry Best Practices  Project/Program Management  Mentoring/Supervision
PROFESSIONAL EXPERIENCE AND ACHIEVEMENTS
MRL Kenilworth, NJ 2011 – 2016
Associate Principal Scientist
Led the efforts for coordinating research direction for 4 postdocs, while simultaneously contributing to
internal projects.
Selected Projects:
 Heme Dependent Enzyme (Atherosclerosis): Identified and optimized one of the main lead
series’ which demonstrated target engagement in vivo.
 GPCR (Hypertension and Cardio Metabolic Disease): Developed a tractable SAR, with good
PK properties which led to tool compounds.
 Synthetase (Infectious disease; an anti-bacterial program): Developed a tractable SAR
with good PK properties. One of the first compounds to demonstrate wild type cell activity in vitro
assay.
 Protein Hormones (Heart Failure): Helped colleagues in biology in order to establish a suitable
assay by developing appropriate tool compounds.
 Heme Dependent Enzyme (An Anti-Bacterial): Repurposing of the tool compounds and
demonstrated in vivo efficacy.
 Malaria (Anti-parasitic program with neglected and tropical disease): Recognized the
potential of repurposing the Merck Small Molec ules for a novel treatment for Malaria. Successfully
demonstrated in vivo efficacy. Contributed significantly to the development, submission, and
defense of proposals for external funding in order to support collaborative malaria-focused
research efforts.
 DPP4 (Diabetes): Participated in a grand challenge and contributed novel design ideas
(sulfoximines) that were selected and resulted in a patent filing (Treating diabetes with dipeptidyl
peptidase-IV inhibitors).
Schering Plough, NJ 2007 – 2011
Senior Scientist
Led comprehensive research efforts for a multitude of projects.

2. Tanweer A. Khan, Ph.D.
Page 2 of 3
Selected Projects:
 Atherosclerosis: Worked on initial triage for a no-go decision.
 Renin (Hypertension): Developed and then discovered lead compounds based on fragment -
based drug design. Demonstrated in vivo efficacy with tool compound.
 A2A (Parkinson’s Disease; Neuroscience): Developed two new series’ with tractable SAR.
New scaffolds were developed as bio isosters of amides, alcohols, and amines.
 BACE (Alzheimer Disease; Neuroscience): Key participant in a grand challenge and
contributed novel design ideas resulting in two patent filings. (Synthesis of S-imino-S-
oxoiminothiazine compounds as BACE inhibitors and Synthesis of S-imino S-oxoiminothiazine
compounds as BACE inhibitors).
ADDITIONAL EXPERIENCE
Florida State University, FL 2005 – 2007
Post-Doctoral Research Fellow
Research Advisor: Professor Robert A. Holton
 Performed studies towards total synthesis of natural product lonomycin A.
 Designed and developed camphor-based chiral auxiliary for asymmetric Michael addition.
University of Strathclyde, UK 2004 – 2005
Post-Doctoral Research Fellow
Research Advisor: Professor John A. Murphy
 Developed a neutral organic molecule as a powerful electron transfer reagent for radical reactions.
 Investigated non-classical Wittig reactions.
University of Strathclyde, UK 2000 – 2004
Graduate Assistant
Mentor: Professor John A. Murphy
 Dissertation “A novel and clean approach towards the total synthesis of spiropyrrolidinyloxindole
and vinca alkaloids.
Indian Institute of Technology (IIT), Kanpur, India 1997 – 2000
Research Assistant
Research Advisor: Professor Javed Iqbal
 Assisted in the design and synthesis of libraries of peptide based, HIV-Protease inhibitors.
 Developed a route for the synthesis of conformationally constrained peptide.
EDUCATION & TRAINING
Ph.D., Chemistry, University of Strathclyde, Glasgow, UK
Masters of Science, Chemistry, Aligarh M. University, UP, India
Bachelors of Science, Chemistry and Zoology, Avadh University, Faizabad, UP, India
Chemical Biology-Purpose, Capabilities, and Future Directions Review
Therapeutic Modalities Beyond Small Molecules
Pharmacology of Drug Discovery
Bacteriology 101 Why Bad Bugs Need New Drugs
Neuroscience for Medicinal Chemists
Leadership Course: Innovate like Edison by Michael J. Gelb
Drew University Residential Medicinal Chemistry Course

3. Tanweer A. Khan, Ph.D.
Page 3 of 3
AWARDS & FELLOWSHIPS
Pathfinder Awards, Wellcome Trust, London, UK
Award of Excellence for New Target Identifications
Award of Excellence for executing Ireland Enterprise Grant
Award for Excellence for IP Challenges
Award for Excellence for Structure-Based Drug Design
Overseas Research Students Award, UK
International Research Scholarship, University of Strathclyde, UK
Best Officer Merit Awards, Students Union, University of Strathclyde, UK
Research Fellowship, Council of Science and Industrial Research, India
Research Fellowship, Graduate Aptitude Test in Engineering, India
PUBLICATIONS
1. Chambers, Rachel; Khan, Tanweer; Olsen, David B. and Sleebs, Brad, Synthesis of amino
heterocycle aspartyl protease inhibitors, Org. Biomol. Chem., 2016, 14, 4970–4985.
2. Gang Zhou, Robert Aslanian, Gioconda Gallo, Tanweer Khan, et al., Discovery of
aminoquinazoline derivatives as human A2A adenosine receptor antagonists,
Bioorganic & Medicinal Chemistry Letters, 2016, 26, 7, 1348-1354.
3. McKittrick, Brian A.; and Tanweer Khan et a.al., Iminopyrimidinones: A novel
pharmacophore for the development of orally active renin inhibitors, Bioorganic &
Medicinal Chemistry Letters, 2015, 25, 1592-1596.
4. V. V. Popik, A. Wright, T. A. Khan and J. A. Murphy, F. Gelat and J-L. Montchamp,
Hypophosphorous acid, Electronic Encyclopaedia of Reagents in Organic Synthesis. May
27, 2014, Wiley & Sons, Ltd; DOI: 10.1002/047084289X.rh075.pub3.
5. G. P. McGlacken and T. A. Khan, Formation of carbanions using neutral organic molecules
as electron-transfer reagents: A radical concept, Angew. Chem. Int.Ed., 2007, 47, 2.
6. J. A. Murphy, T. A. Khan, S. Zhou, D. W. Thomson, M. Mohan, Highly efficient reduction of
unactivated aryl and alkyl iodides by a ground-state neutral organic electron donor,
Angew. Chem. Int. Ed., 2005, 44, 1356.
7. J. A. Murphy, R. Tripoli, T. A. Khan and U. W. Mali, Novel phosphorus radical-based routes to
horsfiline, Org. Lett., 2005, 7, 3287.
8. J. A. Murphy, A. G. J. Commeureuc, T. N. Snaddon, T. M. McGuire, T. A. Khan, M. L. Dewis and R.
Carling, Direct Conversion of N-Methoxy-N-Methylamines to Ketones via a non-Classical
Wittig Reaction, Org. Lett., 2005, 7, 1427.
9. S. Lang, M. Corr, N. Muir, T. A. Khan, F. Schonebeck, J. A. Murphy, A. H. Pyne and A. C. Williams,
Tetrahedron Lett., 2005, 46, 4027.
10. T. A. Khan, R. Tripoli, J. J. Crawford, C. G. Martin, J. A. Murphy, Diethyl-phosphine oxide
(DEPO): High-yielding and facile preparation of indolones in water, Org. Lett., 2003, 5,
2971.
11. A. Wright, T. A. Khan and J. A. Murphy, Electronic Encyclopaedia of Reagents in Organic
Synthesis. Article RH075, 2003, Edited by L. Paquette, P. Fuchs, D. Crich and P. Wipf, John
Wiley & Sons, Ltd.
12. Manuscript in preparation: Pd nanocubes in the assessment of catalyst shape in a direct
acylation/C-H activation reaction, Leticia Pardo, John O’Connell, Gillian Collins, Tom
O’Ceallaigh, Tanweer Khan, Justin Holmes and Gerard McGlacken*.
13. Manuscript in preparation: Efficient cross coupling of a difficult substrate class: Access
to amino triazoles/tetrazoles, Rafael Cano, Tom O’Ceallaigh, Tanweer Khan and Gerard
McGlacken*.

4. Tanweer A. Khan, Ph.D.
Page 4 of 3
Patents and patent applications
1. Aminoquinoline compounds as A2A antagonist, Ali, Amjad; Zhou, Gang, Khan Tanweer A.,
et al., PCT Int. Appl. (2016), WO 2016126570 A1 20160811.
2. Synthesis of S-imino-S-oxoiminothiazine compounds as BACE inhibitors, Khan,Tanweer
A.; Scott, Jack D.; Cumming, Jared N. From PCT Int.
Appl. (2014), WO 2014150331 A1 20140925.
3. S-imino-s-oxo iminothiadiazine compounds as BACE inhibitors, compositions, and their
use, Khan, Tanweer A.; Scott, Jack D.; Cumming, Jared N. PCT Int.
Appl. (2014), WO 2014150340 A1 20140925
4. Treating diabetes with dipeptidyl peptidase-IV inhibitors, Biftu, Tesfaye; Khan, Tanweer A.
PCT Int. Appl. (2014), WO 2014018355 A1 20140130.
5. Preparation of N3-substituted iminopyrimidinones as renin inhibitors, compositions,
and their use. Khan, Tanweer; Josien, Hubert; Mckittrick, Brian; Vaccaro, Henry; Bara, Thomas;
Caldwell, John; Heap, Charles R.; Geiss, William B.; Mitra, Sumya; Zych, Andrew J. PCT Int.
Appl. (2013), WO 2013142396 A1 20130926.
6. 2 patents applications were already filed and 5 more patents applications are in process and
cannot be disclosed at this moment